

Quality Incentive Pool (QIP) Benchmarks—PY 3 v.1

Only metrics with released benchmarks are shown here. This document will be updated as more benchmarks are released. Benchmarks subject to change.

Performance	QIP ID	NQF#	Quality ID #	Title	25 th /min.(%)	90 th /top perf. (%)	Benchmark Source/ Notes
Primary Care Measures							
P	Q-PC1			Comprehensive Diabetes Care: A1C Control (<8%) (CDC-H8)	44.44	59.49	NCQA Quality Compass – Medicaid 2018; HMO Average
P	Q-PC2			Comprehensive Diabetes Care: Eye Exam (CDC-E)	50.85	68.61	NCQA Quality Compass – Medicaid 2018; HMO Average
P	Q-PC3			Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)	56.2	77.5	NCQA Quality Compass – Medicaid 2018; HMO Average
P	Q-PC4			Asthma Medication Ratio (AMR)	56.85	71.93	NCQA Quality Compass – Medicaid 2018; HMO Average
P	Q-PC5			Medication Reconciliation Post Discharge (MRP)	38.69	77.62	NCQA HEDIS Medicare 2018
P	Q-PC7			Children and Adolescent Access to PCP (CAP) <ul style="list-style-type: none"> • 12-24 Months • 25 Months-6 Years • 7-11 Years • 12-19 Years 	93.64 84.39 87.73 85.81	97.71 92.88 96.18 94.75	NCQA Quality Compass – Medicaid 2018; HMO Average
P	Q-PC9			Immunizations for Adolescents (IMA) Combination 2	26.28	46.72	NCQA Quality Compass – Medicaid 2018. Updated to account for trending break.
P	Q-PC10			Childhood Immunization Status (CIS) Combination 10	28.00	48.00	DHCS
P	Q-PC11	2903		Contraceptive Care – All Women (CCW) Most and Moderately Effective Methods, Ages 15-44	18.55	24.58	Based on administrative encounter data retrieved by DHCS as of January 2019 for calendar year 2017 dates of service; percentiles are based on ranking of 53 health plan reporting groups.
P	Q-PC12	0033		Chlamydia Screening in Women (CHL), Ages 16-24	51.00	71.00	DHCS
P	Q-PC13	2082/3210e		HIV Viral Load Suppression (HVL-AD)	66.36	82.26	Based on administrative encounter data retrieved by DHCS as of January 2019 for calendar year 2017 dates of service; percentiles are based on ranking of 49 health plan reporting groups (5 reporting groups with a sample size of less than 30 were excluded).
P	Q-PC14	1392		Well-Child Visits in the First 15 Months of Life (W15-CH), Six or more well-child visits	59.00	75.00	DHCS

Performance	QIP ID	NQF#	Quality ID #	Title	25 th /min.(%)	90 th /top perf. (%)	Benchmark Source/ Notes
Specialty Care Measures							
P	Q-SC1	1525	326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	25.00	90.00	Medicare: 90 th : Not Available. 30 th : claims-96.85% Methodology for metrics with only Medicare benchmarks: Medicare high performance minus 8% vs 90%, whichever is lower. The 8% adjustment was based on comparison of Medicaid to Medicare rates for the IVD ASA measure.
P	Q-SC2	0067	006	Coronary Artery Disease (CAD): Antiplatelet Therapy	50.00	88.00	Medicare 90 th : 95.99% 30 th : 74.18% (registry) Methodology for metrics with only Medicare benchmarks: Medicare high performance minus 8% vs 90%, whichever is lower. The 8% adjustment was based on comparison of Medicaid to Medicare rates for the IVD ASA measure.
P	Q-SC3	0066	118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	50.00	90.00	Medicare 90 th : 99.99% 30 th : 81.75% Methodology for metrics with only Medicare benchmarks: Medicare high performance minus 8% vs 90%, whichever is lower. The 8% adjustment was based on comparison of Medicaid to Medicare rates for the IVD ASA measure.
P	Q-SC4	0070	007	Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	50.00	90.00	Medicare 90 th : Not available 30 th : EMR-77.41%, Registry: 80.55% Methodology for metrics with only Medicare benchmarks: Medicare high performance minus 8% vs 90%, whichever is lower. The 8% adjustment was based on comparison of Medicaid to Medicare rates for the IVD ASA measure.
P	Q-SC5	0081 eMeasure NQF 2907	005 eMeasure ID: CMS135v6	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction	50.00	83.00	Medicare 90 th : EMR-90.90%, Registry-96.54% 30 th : EMR-66.66%, Registry-79.48% Methodology for metrics with only Medicare benchmarks: Medicare high performance minus 8% vs 90%, whichever is lower. The 8% adjustment was based on comparison of Medicaid to Medicare rates for the IVD ASA measure.

Performance	QIP ID	NQF#	Quality ID #	Title	25 th /min.(%)	90 th /top perf. (%)	Benchmark Source/ Notes
P	Q-SC6	0083 eMeasure NQF 2908	0 ID #008 eMeasure ID CMS144v6)	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction	50.00	88.00	Medicare 90 th : EMR-95.99%, Registry-99.99% 30 th : EMR-64.70%, Registry-81.01% Methodology for metrics with only Medicare benchmarks: Medicare high performance minus 8% vs 90%, whichever is lower. The 8% adjustment was based on comparison of Medicaid to Medicare rates for the IVD ASA measure.
Inpatient Care Measures							
P ↓	Q-IP1			Surgical Site Infection (SSI)	SIR = 1.254	SIR = 0.538	25 th and 75 th percentiles of the CDPH 2016 Aggregate of the 6 procedures chosen for QIP
P	Q-IP2	268	21	Perioperative Care: Selection of Prophylactic Antibiotic – 1st OR 2nd Generation Cephalosporin	25.00	90.00	No national benchmark Utilized standard NQCA methodology
P	Q-IP3	239	23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis	25.00	90.00	No national benchmark DSRIP data available. DPHs performed up to 95% in DY10.
P	Q-IP4		76	Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections	25.00	90.00	No national benchmark DPHs worked on central line infections in DSRIP
P	Q-IP5		407	Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia	25.00	90.00	Based on available preliminary DPH data
P	Q-IP6			Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)	25.00	90.00	No national benchmark 5 DPHs worked on stroke in DSRIP, and in DY10 performed at 95-99% for this measure
Resource Utilization Measures							
P ↓	Q-RU1		322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)	75.00	10.00	No national benchmark Utilized standard NQCA methodology
P	Q-RU2		415	Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older	50.00	90.00	Based on available Medicare QPP 2018 data
P ↓	Q-RU3		416	Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old	50.00	10.00	Based on available Medicare QPP 2018 data for Q-RU2
P ↓	Q-RU5			Concurrent Use of Opioids and Benzodiazepines	16.75	9.43	Based on administrative encounter data retrieved by DHCS as of January 2019 for calendar year 2017 dates of service; percentiles are based on ranking of 53 health plan reporting groups.

Performance	QIP ID	NQF#	Quality ID #	Title	25 th /min.(%)	90 th /top perf. (%)	Benchmark Source/ Notes
P ↓	Q-RU6	2940		Use of Opioids at High Dosage in Persons Without Cancer	3.32	1.07	Placeholder; final benchmark to be released as soon as it is available. Based on administrative encounter data retrieved by DHCS as of January 2019 for calendar year 2017 dates of service; percentiles are based on ranking of 53 health plan reporting groups.

Performance column shows that a lower rate (↓) indicates better performance, when applicable.